Six key targets, JUN, CASP3, NOS3, PTGS2, HSP90AA1, and NR3C1, were selected for molecular docking with β-sitosterol, stigmasterol, ferulic acid, carotenoid, anthocyanin, and 5-hydroxymethylfurfural, which are the core active components in the treatment of HF. The gene discussed is NR3C1; the disease is hydrops fetalis.